09:26 AM EST - Oncolytics Biotech Inc : Announced an update on the proposed design of its planned registration-directed clinical trial in first-line pancreatic ductal adenocarcinoma (PDAC). The Company is currently scheduled to meet with the U.S. Food and Drug Administration in mid-November 2025 to advance study details. Oncolytics Biotech Inc
shares N.ONCY are trading up $0.04 at $1.29.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=6648545338379621
